Dalbavancin
- PDF / 169,889 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 31 Downloads / 155 Views
1
S
Fever and renal failure: 2 case reports In a multi-centre, observational, retrospective study of 83 patients (DALBACEN cohort) performed from 2016 to 31 December 2017, two patients [ages and sexes not stated] were described, who developed fever or renal failure (1 patient each) during consolidation therapy with dalbavancin for infective endocarditis [not all routes stated; durations of treatment to reactions onset stated]. Case 1: A patient, who had early prosthetic valve endocarditis with methicillin-resistant Staphylococcus aureus, started receiving dalbavancin 1500mg for one day, followed by 500mg for 8 days and again for 15 days. However, the patient subsequently developed self-limiting fever. The therapy was not discontinued. Case 2: A patient, who had pacemaker lead endocarditis with Staphylococcus epidermidis, started receiving IV dalbavancin 1500mg for one day. However, the patient subsequently developed renal failure, which returned to baseline status in one week. The therapy was not discontinued. Author comment: "Among the 83 patients who received [dalbavancin], 4.8% experienced adverse effects: asthenia, self-limited rash, fever with self-limited shivering, and impaired renal function that was found by laboratory tests to have returned to its baseline status at one week [Table 3]." Hidalgo-Tenorio C, et al. DALBACEN cohort: Dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci. Annals of Clinical Microbiology and Antimicrobials 18: 30, No. 1, 19 Oct 2019. Available from: URL: http://doi.org/10.1186/ 803435759 s12941-019-0329-6 - Spain
0114-9954/19/1780-0001/$14.95 Adis © 2019 Springer Nature Switzerland AG. All rights reserved
Reactions 23 Nov 2019 No. 1780
